Pembrolizumab Combined with Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma (Keystone-001)
| Title | Pembrolizumab Combined with Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma (Keystone-001) |
|---|---|
| Description | Combining immunotherapy andchemotherapy is a standard treatment strategy for advanced esophageal squamous cell carcinoma (ESCC).However, the efficacy of this approachin the neoadjuvant treatment of resectable ESCCremains unclear. In this prospective, single-arm, single-center, phase II study, patients with locally advanced,resectable ESCC naive to systemic treatment received three cycles of pembrolizumab plus chemotherapy, followed by Da Vinci robot-assisted surgery. Patients achieving a postoperative non-pathological complete response (pCR) received adjuvant pembrolizumab maintenance therapy. The primary endpoints weresafety and major pathological response (MPR). Key secondary endpoints were pCR and survival. Other endpoints included quality of life (QoL) and nutritional status, programmed death-expressing ligand 1expression, andmulti-omicsanalyses. |
| Organism | Homo sapiens |
| Data Type | Metabolome Data by Mass Spectrometry (MS) |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA019485 |
| Release Date | 2024-09-13 |
| Submitter | Hongjing Jiang (18622923282@163.com) |
| Organization | Tianjin Medical University Cancer Institute and Hospital |
| Submission Date | 2023-09-07 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX004869-01 | Raw_files-X101SC21041991-Z01-J092-B92-42.zip | 38 | Metabolome Data by Mass Spectrometry (MS) | 3.26 GB | zip | 0 | Controlled |